Effectiveness of neoton in patients with chronic heart failure depending on the left ventricular ejection fraction. Sub-analysis of the BYHEART study

Aim. To study the effectiveness of exogenous phosphocreatine (EPCr) therapy in patients with heart failure (HF) with reduced and mildly reduce dejection fraction (EF).

Material and methods. The all-Russian prospective observational study BYHEART included 842 patients who underwent aEPCr therapy course. Before and after the course of EPCr therapy, the following studies were carried out: a questionnaire on the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the clinical assessment scale (CAS), transthoracic echocardiography with an assessment of the left ventricular EF, a 6-minute walk test, N-terminal pro-brain natriuretic peptide (NT-proBNP). All patients before the EPCr course received long-term optimal therapy for HF.

Results. Data analysis was carried out for patients in groups with heart failure with reduced ejection fraction (HFrEF) and with mildly reduced ejection fraction (HFmrEF) within the group depending on the course of EPCr treatment: subgroup A — patients who received EPCr therapy less than 20 g/course and subgroup B — patients who received EPCr therapy ≥20 g/course. The results obtained demonstrate an increase in the quality of life and exercise tolerance, an improvement according to the CAS, a decrease in NT-proBNP levels, and an improvement in left ventricular systolic function in patients with both HFrEF and HFmrEF during the course of intravenous EPCr therapy.

Conclusion. The use of EPCr is a promising tool in addition to optimal therapy in patients with HFrEF and HFmrEF.

1. Tsao CW, Lyass A, Enserro D, et al. Temporal Trends in the Incidence of and Mortality Associated with Heart Failure with Preserved and Reduced Ejection Fraction. JACC Heart Failure. 2018;6(8):678-85. doi:10.1016/j.jchf.2018.03.006.

2. Shah KS, Xu H, Matsouaka RA, et al. Heart Failure with Preserved, Borderline, and Reduced Ejection Fraction. Journal of the American College of Cardiology. 2017;70(20):2476-86. doi:10.1016/j.jacc.2017.08.074.

3. Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.) doi:10.18087/cardio.2021.4.n1628.

4. Tereshchenko SN, Cheremisina IA, Safiullina AA. The possibilities of improving the treatment of chronic heart failure according to the results of a multicenter observational study BYHEART. Therapeutic Archive. 2022;94(4):517-23. (In Russ.) doi:10.26442/00403660.2022.04.201450.

5. Tereschenko SN, Perepech NB, Cheremisina IA, et al. Interim Results of the BYHEART Observational Study: Exogenous Phosphocreatine Effect on the Quality of life of Patients with Chronic Heart Failure. Kardiologiia. 2021;61(7):22-7. (In Russ.) doi:10.18087/cardio.2021.7.n1649.

6. Tereshchenko SN, Perepech NB, Cheremisina IA. BYHEART observational trial of assessing exogenous phosphocreatine influence on the quality of life in patients with congestive heart failure. Cardiology and Cardiovascular Surgery. 2020;13(2):168-70. (In Russ.) doi:10.17116/kardio202013021168.

7. Grazioli I, Melzi G, Strumia E. Multicenter controlled study of creatine phosphate in the treatment of heart failure. Curr Therap Res. 1992;52:271-80.

8. Andreev N, Andreva T, Bichkov I. Effect of phosphocreatine in congestive heart failure. Curr Ther Res. 1992;51:649-60.

9. Mikhin VP, Nikolenko TA, Gromnatskiy NI. The Efficacy of Creatine Phosphate as Part of Complex Therapy in Patients with Chronic Heart Failure and History of ST-elevation Myocardial Infarction. Lechebnoe delo. 2020;(1):64-70. (In Russ.) doi:10.24411/2071-5315-2020-12194.

10. Carmenini G. Controlled multicentric clinical study with placebo in patients with dilatative myocardiopathy functional class II‐III N.Y.H.A. treated with oral phosphocreatinine. Сuore rivista di cardiochirurgia e cardiologia. 1994;11(2):187‐93.

11. Wang FR, Zheng X. Effects of phosphocreatine on plasma brain natriuretic peptide level and left ventricular function in patients with heart failure. Liaoning: Affl iated Hospital, Chinese Medicine University. Published at PJCCPVD. August 2008;16:29-31.

12. Du XH, Liang FY, Zhao XW. Effects of phosphocreatine on plasma brain natriuretic peptide level in elderly patients with chronic congestive heart failure. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(1):154-5, 159. Chinese.

13. Peng W. Clinical effect of sodium creatine phosphate in the treatment of chronic heart failure. Chinese Medicine. 2013;8(9). doi:10.3760/cma.j.issn.1673-4777.013.09.004.

14. Simakov AA, Poliaeva LV, Riazanova EI. Optimization of treatment of chronic heart failure in patients with ischemic heart disease. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2014;7(5):20-3. (In Russ.)

15. Jing Z. Efficacy of sacubitril valsartan combined with sodium creatine phosphate in the treatment of chronic heart failure. Chinese Journal of Practical Medicine. Sep. 2020;47(18). doi:10.3760/cma.j.cn115689-20200604-02804.

16. Li X H, Xing Y Q, Zhang X, et al. Clinical efficacy of exogenous phosphocreatine in the treatment of elderly patients with chronic heart failure and its impact on heart failure markers. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease. 2020;28(6):42-6.